Aim: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy. Methods: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. χ2 tests were used for comparisons of interest across groups. Results: Respondents were 68% male and 53% African-American, with a mean age of 47 years. Overall, 73% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61% with weekly dosing; 72% every 2 weekly; and 84% monthly. In total, 48% indicated that they were very concerned about the possible side effects and 35% were very concerned about needle use. Conclusion: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy.

Original languageEnglish (US)
Pages (from-to)1807-1813
Number of pages7
Issue number11
StatePublished - Nov 2013


  • AIDS
  • HIV
  • antiretroviral therapy
  • intravenous drug abuse
  • nanoformulated antiretroviral therapy
  • nonadherence
  • substance abuse

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)


Dive into the research topics of 'Long-acting parenteral nanoformulated antiretroviral therapy: Interest and attitudes of HIV-infected patients'. Together they form a unique fingerprint.

Cite this